Status: Not yet recruiting
SGLT2 Inhibitors as a Novel Treatment for Pediatric Non-Alcoholic Fatty Liver Disease
This study is a randomized, double-blind, placebo-controlled trial specifically designed to evaluate the preliminary feasibility, initial efficacy and safety of SGLT2 inhibitors for treating NAFLD in adolescents with obesity.
Participants needed: 40
Trial details
Phase: Phase 2Age: 12-20Biological sex: AllType: InterventionalSponsor: Justin RyderUpdated: Jan 20, 2026Locations: 1
Eligibility criteria
Age: 12 to <20 years old [+9]
ALT > 250U/L at screening [+34]